← All trials
NCT04391049
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2020
- Primary completion
- Oct 1, 2021
- Completion date
- Oct 1, 2023
- First posted
- May 18, 2020
- Last posted
- May 20, 2020
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NRG OncologyLead sponsor
- National Cancer Institute (NCI)Collaborator
- NRG OncologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.